Twist Bioscience (NASDAQ:TWST) Given New $35.00 Price Target at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST) had its price target upped by JPMorgan Chase & Co. from $28.00 to $35.00 in a research note published on Monday morning, Benzinga reports. They currently have an underweight rating on the stock.

A number of other analysts have also recently weighed in on the company. The Goldman Sachs Group boosted their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock a buy rating in a research report on Tuesday, July 9th. TD Cowen boosted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a buy rating in a research report on Thursday, June 13th. Scotiabank boosted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a research report on Monday, May 6th. Robert W. Baird upped their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an outperform rating in a report on Monday. Finally, Evercore ISI upped their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an outperform rating in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $48.22.

Twist Bioscience Stock Up 2.0 %

Shares of NASDAQ TWST opened at $45.42 on Monday. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -13.52 and a beta of 1.80. The stock’s fifty day simple moving average is $50.88 and its 200 day simple moving average is $41.63. Twist Bioscience has a 52-week low of $14.42 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter in the prior year, the firm posted ($1.01) EPS. The business’s quarterly revenue was up 27.7% compared to the same quarter last year. As a group, analysts anticipate that Twist Bioscience will post -3.13 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,408 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $123,602.64. Following the transaction, the chief executive officer now directly owns 507,578 shares in the company, valued at approximately $26,053,978.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total value of $124,960.34. Following the transaction, the chief operating officer now directly owns 171,212 shares in the company, valued at approximately $9,694,023.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 2,408 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $123,602.64. Following the completion of the transaction, the chief executive officer now owns 507,578 shares in the company, valued at $26,053,978.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,327 shares of company stock worth $978,760. Insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the 4th quarter worth $30,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Nisa Investment Advisors LLC raised its stake in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares during the period. Finally, CWM LLC raised its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.